Article | September 15, 2022

Linking CAR-T's Cytokine Releases Syndrome Risk To Common Biomarkers In New Study

Source: Medidata AI

By Annalee Armstrong, Senior Editor

Embryonic Stem Cells GettyImages-1135352068

As CAR T-cell therapy becomes more common in oncology, predicting the patients who may experience the life threatening complication called cytokine release syndrome (CRS) is becoming more important. But while many companies are studying these therapies, trials tend to be small, meaning it’s difficult to ascertain which patients might be at risk. 

A clinical trial software provider rolled out a new study at the 2022 American Society of Clinical Oncology (ASCO) conference that pooled data from 542 patients across multiple clinical trials that have been conducted with CAR-T therapies in an effort to gain more insight into which patients are likely to experience CRS.


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader